Price
Frequently asked questions
What is Idorsia's market capitalization?
What is the Earnings Per Share (EPS) for Idorsia?
What are the analyst ratings and target price for Idorsia's stock?
What is Idorsia's revenue over the trailing twelve months?
What is the EBITDA for Idorsia?
What is the free cash flow of Idorsia?
What is the 5-year beta of Idorsia's stock?
How many employees does Idorsia have, and what sector and industry does it belong to?
What is the free float of Idorsia's shares?
Financials
Market Cap
$160.34M5Y beta
2.18EPS (TTM)
-$1.891Free Float
120.09MRevenue (TTM)
$83.25MEBITDA (TTM)
-$422.06MFree Cashflow (TTM)
-$548.54MPricing
Analyst Ratings
The price target is $1.915 and the stock is covered by 9 analysts.
Buy
0
Hold
4
Sell
5
Information
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
938
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker